Evangelos Tsipotis

Evangelos Tsipotis

Auto-generated profile, based on publicly available information

Evangelos Tsipotis

Department of Medicine, St. Elizabeth's Medical Center, Tufts University School of Medicine, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2015 in Advances in Chronic Kidney Disease
Verified
Journal Article
Closed access
ETEvangelos Tsipotis
Evangelos Tsipotis
ASAsim Shuja
Asim Shuja
BJBertrand L. Jaber
Bertrand L. Jaber

1 January 2018 in The American Journal of Medicine
Verified
Journal Article
Closed access
ETEvangelos Tsipotis
Evangelos Tsipotis
LPLori Lyn Price
Lori Lyn Price
BJBertrand L. Jaber
Bertrand L. Jaber
NMNicolaos E. Madias
Nicolaos E. Madias

31 August 2016 in American Journal of Nephrology
Verified
Journal Article
Open access
PDF file
ETEvangelos Tsipotis
Evangelos Tsipotis
NGNavin R. Gupta
Navin R. Gupta
GRGowri Raman
Gowri Raman
EZElias Zintzaras
Elias Zintzaras
BJBertrand L. Jaber
Bertrand L. Jaber
Background: Concerns exist over the extrapolation of bioavailability studies of generic immunosuppressive drugs in healthy volunteers, regarding their efficacy and safety in kidney transplant recipients. We conducted a meta-analysis of trials examining the bioavailability of generic (test) immunosuppressive drugs relative to their brand (reference) counterparts in healthy volunteers, based on the US Food and Drug Administration requirements for approval of generics, and their efficacy and safety in kidney transplant recipients. Methods: Eligible studies were identified in PubMed, Cochrane Central Register of Controlled Trials, Scopus, ClinicalTrials.gov, and conference abstracts. Results: Twenty crossover trials of healthy volunteers (n = 641) and 6 parallel-arm randomized controlled trials of kidney transplant recipients (n = 594) were identified. The 90% CI of the pooled test-to-reference drug ratio for maximum or peak plasma concentration (Cmax) and area under the plasma concentration time-curve from time 0 to time of last determinable concentration (AUC(0-t)) fell within the required range (0.80-1.25) for cyclosporine (Cmax 0.91; 90% CI 0.86-0.95; and AUC(0-t) 0.97; 90% CI 0.94-1.00), tacrolimus (Cmax 1.17; 90% CI 1.09-1.24; and AUC(0-t) 1.00; 90% CI 0.97-1.03) and mycophenolate mofetil (Cmax 0.98; 90% CI 0.96-1.01; and AUC(0-t) 1.00; 90% CI 0.99-1.01). In subgroup analyses, some generic cyclosporine formulations did not meet criteria for bioequivalence. No significant differences were observed in the time to maximum plasma concentration and terminal plasma half-life between generic and brand drugs. In parallel-arm trials, generic cyclosporine was non-inferior to brand counterpart in terms of acute allograft rejection, infections, and death. Conclusions: Not all generic immunosuppressive drugs have similar relative bioavailability to their brand name counterparts. Evidence on their efficacy and safety is inconclusive. Tighter regulatory requirement for approval of generic drugs with narrow therapeutic index is needed.

11 April 2018 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
ETE. Tsipotis
E. Tsipotis
GLG. I. Leontiadis
G. I. Leontiadis